13,154 Shares in Neurocrine Biosciences, Inc. $NBIX Acquired by Fideuram Intesa Sanpaolo Private Banking S.P.A.

Fideuram Intesa Sanpaolo Private Banking S.P.A. acquired a new position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) during the 4th quarter, HoldingsChannel.com reports. The fund acquired 13,154 shares of the company’s stock, valued at approximately $1,866,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. AlTi Global Inc. grew its stake in Neurocrine Biosciences by 1.0% in the third quarter. AlTi Global Inc. now owns 6,828 shares of the company’s stock worth $959,000 after purchasing an additional 70 shares in the last quarter. Vanguard Personalized Indexing Management LLC grew its stake in Neurocrine Biosciences by 0.7% in the third quarter. Vanguard Personalized Indexing Management LLC now owns 11,112 shares of the company’s stock worth $1,560,000 after purchasing an additional 77 shares in the last quarter. Perigon Wealth Management LLC grew its stake in Neurocrine Biosciences by 3.1% in the fourth quarter. Perigon Wealth Management LLC now owns 2,590 shares of the company’s stock worth $367,000 after purchasing an additional 78 shares in the last quarter. Signaturefd LLC grew its stake in Neurocrine Biosciences by 4.5% in the fourth quarter. Signaturefd LLC now owns 1,925 shares of the company’s stock worth $273,000 after purchasing an additional 83 shares in the last quarter. Finally, Great Lakes Advisors LLC grew its stake in Neurocrine Biosciences by 2.4% in the third quarter. Great Lakes Advisors LLC now owns 3,605 shares of the company’s stock worth $506,000 after purchasing an additional 84 shares in the last quarter. Institutional investors own 92.59% of the company’s stock.

Insider Buying and Selling at Neurocrine Biosciences

In other news, Director Leslie V. Norwalk sold 3,810 shares of the stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $155.01, for a total transaction of $590,588.10. Following the completion of the sale, the director owned 2,429 shares in the company, valued at approximately $376,519.29. This represents a 61.07% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richard F. Pops sold 15,000 shares of the stock in a transaction on Friday, May 15th. The shares were sold at an average price of $157.65, for a total value of $2,364,750.00. Following the sale, the director owned 34,480 shares of the company’s stock, valued at approximately $5,435,772. This represents a 30.32% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 263,898 shares of company stock valued at $40,779,769. 4.60% of the stock is currently owned by corporate insiders.

Neurocrine Biosciences Trading Up 0.5%

Shares of NASDAQ NBIX opened at $155.50 on Friday. The stock has a market capitalization of $15.64 billion, a PE ratio of 23.96, a price-to-earnings-growth ratio of 1.16 and a beta of 0.34. The stock’s fifty day simple moving average is $136.13 and its two-hundred day simple moving average is $138.77. Neurocrine Biosciences, Inc. has a 12-month low of $117.59 and a 12-month high of $162.39.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on NBIX shares. Zacks Research raised Neurocrine Biosciences from a “strong sell” rating to a “hold” rating in a research note on Wednesday, April 15th. Canaccord Genuity Group increased their target price on Neurocrine Biosciences from $164.00 to $200.00 and gave the company a “buy” rating in a research report on Tuesday, April 7th. Truist Financial increased their target price on Neurocrine Biosciences from $140.00 to $155.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. HC Wainwright increased their target price on Neurocrine Biosciences from $192.00 to $215.00 and gave the company a “buy” rating in a research report on Tuesday, April 7th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $185.00 target price on shares of Neurocrine Biosciences in a research report on Monday, April 6th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and five have given a Hold rating to the company. According to MarketBeat.com, Neurocrine Biosciences presently has a consensus rating of “Moderate Buy” and an average target price of $184.15.

About Neurocrine Biosciences

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research?driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.